ITCI(Delisted)
Intra-cellularยทNASDAQ
--
--(--)
ITCI Profile
Intra-Cellular Therapies, Inc.
A biopharmaceutical company that develops therapeutics for central nervous system (CNS) disorders
135 Route 202/206, Suite 6, Bedminster, New Jersey, 07921
--
Intra-cellular Therapies, Inc., was incorporated in Delaware on May 22, 2001 and began operations in June 2002. The company was founded to develop drugs for the treatment of neurological and psychiatric diseases. ITI is a biopharmaceutical company focused on innovating and developing clinical small molecule drugs to improve medical conditions for mental disorders in the central nervous system. The company's leading product, ITI-007, has been clinically developed into a first-class drug for the treatment of schizophrenia. Drugs currently used to treat schizophrenia also do not fully address a range of symptoms of central nervous system disease. These existing drugs are also limited by their powerful side effects. ITI-007 is used to treat many symptoms, including acute and residual schizophrenia, with improved safety and tolerability.
